Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
NCT03672175 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
- Lead sponsor
- Biogen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 19, 2018
- Completion date
- March 17, 2020
- Enrollment
- 581 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.